Researchers at the University of Waterloo's School of Pharmacy have combined the anti-amyloid antibodies already used in Alzheimer's treatment with small molecules derived from micronutrients found in grapes, berries, peanuts and turmeric. In their study, the pairing neutralized the clumping of the toxic amyloid proteins that accumulate in the brains of people with Alzheimer's, producing better results than either component working alone.
The appeal of the approach lies in dosing. Anti-amyloid antibody therapies can slow the disease, but they carry risks that can be fatal, including brain swelling and bleeding. If a companion molecule takes on part of the work of breaking up amyloid, clinicians may be able to prescribe lower antibody doses and reduce the chance of those serious side effects, the researchers suggest.
None of the individual pieces are new. Resveratrol and curcumin, the small molecules at the center of the work, were already known to block amyloid buildup. What the Waterloo team is proposing is the pairing itself, treating the two agents as partners rather than competing strategies.
That distinction matters for a disease with no cure, where most available medications only ease symptoms. Dementia affects nearly 750,000 people in Canada, and the country is expected to reach a million cases by 2030. The findings describe a laboratory result rather than a tested therapy, so the next question is whether the combination holds up in people and whether lower antibody doses genuinely translate into a safer treatment.